Parkman Healthcare Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parkman Healthcare Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,136,413	Closed	-$1.24M	–	99
2023 Q3	$1.24M	Sell	1,136,413 -194,203	-15%	-$341K	0.23%	89
2023 Q2	$3.05M	Buy	1,330,616 +655,288	+97%	+$1.74M	0.53%	57
2023 Q1	$1.64M	Buy	675,328 +254,126	+60%	+$582K	0.36%	65
2022 Q4	$804K	Buy	421,202 +117,588	+39%	+$250K	0.21%	74
2022 Q3	$729K	Buy	303,614 +53,614	+21%	+$148K	0.21%	79
2022 Q2	$465K	Buy	+250,000	New	+$477K	0.17%	70

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Parkman Healthcare Partners's LXRX Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 1,136,413 shares — an estimated $1.24M sold.

Parkman Healthcare Partners first reported a position in LXRX in Q2 2022 and held it in 6 quarters. The position peaked at $3.05M in Q2 2023. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.

Parkman Healthcare Partners reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 1,136,413 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $1.24M.
Parkman Healthcare Partners first reported a position in Lexicon Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Parkman Healthcare Partners's Lexicon Pharmaceuticals position peaked at $3.05M in Q2 2023.
106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.